|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment selection for patients with metastatic renal cell carcinoma显示文摘 | ATKINS MB CHOUEIR1 TK CHO D | 2009 | Cancer2009，115，10： | 1 |
| 2 | Adjuvant high-dose bolus intedeukin-2 for patients with high-risk renal cell carcinoma : a cytokine working group randomized trial 显示文摘 | Clark JI Atkins MB Urba WJ | 2003 | J Clin Oncol2003，21，16： | 1 |
| 3 | Phase Ⅲ trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cis- platin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinat- ed by the Eastern Cooperative Oncology Group 显示文摘 | Atkins MB Hsu J Lee S | 2008 | J Clin Oncol2008，26，35： | 1 |
| 4 | Opportunities and obsta- cles to combination targeted therapy in renal cell cancer显示文摘 | Sosman JA Puzanov I Atkins MB | 2007 | Clin Cancer Res2007，13，22： | 1 |
| 5 | High-dose recombinant i nterleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 显示文摘 | Atkins MB Lotze MT Dutcher JP | 1999 | J Clin Oncol1999，17，7： | 1 |
| 6 | Results of a multicenter, randomized, double-blind,dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignanl melanoma 显示文摘 | Glaspy J Atkins MB Richards JM | 2009 | Cancer2009，115，22： | 1 |
| 7 | Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion 显示文摘 | Rodriguez PC Atkins MB Hernandez C | 2005 | Cancer Res2005，65，： | 1 |
| 8 | Phase Ⅲ trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group 显示文摘 | Atkins MB Hsu J Lee S | 2008 | J Clin Oncol2008，26，35： | 1 |
| 9 | Applicayion of IL - 2 and other cyto-kines in renal cancer显示文摘 | McDermott DF Atkins MB | 2004 | Expret Opin Biol Ther2004，4940，： | 1 |
| 10 | High-dose recombinant in- terleukin 2 therapy for patients with metastatic melanoma:analysis of 270 patients treated between 1985 and 1993 显示文摘 | Atkins MB Lotze MT Dutcher JP | 1999 | J Clin Oncol1999，17，7： | 1 |
| 11 | Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcino- ma显示文摘 | Atkins MB Hidalgo M Stadler WM | 2004 | J Clin Oncol2004，22，5： | 1 |
| 12 | Randomized phase Ⅱ study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor in patients with advanced re- fractory renal cell carcinoma 显示文摘 | Atkins MB Hidalgo M Stadler WM | 2004 | J Clin Oncol2004，22，5： | 1 |
| 13 | Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma:a cytokine working group randomized trial显示文摘 | CLARK JI ATKINS MB URBA WJ | 2003 | J Clin Oncol2003，21，16： | 1 |
| 14 | A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stageⅢ or stage IV melanoma显示文摘 | Hodi FS Friedlander PA Atkins MB | 2011 | J Clin Oneol2011，29，： | 1 |
| 15 | PD-1 as a potential target in cancer therapy显示文摘 | McDermott DF Atkins MB | 2013 | Cancer Meal2013，2，5： | 1 |
| 16 | Treatment selection for patients with metastatic renal cell carcinoma 显示文摘 | Atkins MB Choueiri TK Cho D | 2009 | Cancer2009，115，10： | 1 |
| 17 | Opportunities and obstacles to combination targeted therapy in renal cell cancer 显示文摘 | Sosman JA Puzanov I Atkins MB | 2007 | Clin Cancer Res2007，13，22： | 1 |
| 18 | High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993显示文摘 | ATKINS MB LOTZE MT DUTCHERJP | 1999 | J Clin Oneol1999，17，7： | 1 |
| 19 | Longitudinal association of dementia and depression 显示文摘 | Snowden MB Atkins DC Steinman LE | 2014 | Am J Geriatr Psychiatry2014，21，14： | 1 |
| 20 | Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma 显示文摘 | Atkins MB Hidalgo M Stadler WM | 2004 | J Clin Oncol2004，22，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员